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Introduction {#sec005}
============

Hepatitis C virus (HCV) is a major cause of chronic liver disease, cirrhosis, and hepatocellular carcinoma \[[@pone.0194149.ref001],[@pone.0194149.ref002]\]. Estimates of global prevalence of HCV infection range from 1.6% to 2.8%, corresponding to 80 to 185 million people \[[@pone.0194149.ref003]--[@pone.0194149.ref005]\]. In the past, HCV was mostly described as being acquired from transfusion of unscreened blood products, injecting drug use, accidental needle sticks, unsterile needle use during the medical procedures, and tattooing \[[@pone.0194149.ref006]--[@pone.0194149.ref008]\]. However, an increasing number of cases of sexually acquired HCV infection have been reported over the past two decades \[[@pone.0194149.ref009]\]; the factors identified to be associated with those incident HCV infections include male gender, an older age, infection with hepatitis B virus (HBV) and other hepatitis virus, substance use, sexually transmitted infections, and HIV infection \[[@pone.0194149.ref010]\].

Because HIV and HCV share the same transmission routes, the occurrence of co-infection is not uncommon. Among the HIV-positive individuals, it is estimated 20--30% are co-infected with HCV, and the disease progression among patients with HIV/HCV co-infection are more prominent compared with patients with HIV or HCV mono-infection \[[@pone.0194149.ref011]\]. The prevalence of HIV/HCV co-infection varies among the different regions and risk groups studied \[[@pone.0194149.ref012]\]. In China, the seroprevalence of HCV infection among HIV-positive injecting drug users (IDUs) ranged from 60% to 90%, with a pooled seroprevalence of 83%, while that among HIV-positive men who have sex with men (MSM) ranged from 0% to 24.2%, with a pooled seroprevalence of 4% \[[@pone.0194149.ref013]\]. In Southeast Asia, the seroprevalence of HCV co-infection among HIV-positive patients was estimated to be 2.9% to 80.8%, with significant regional differences \[[@pone.0194149.ref013]\].

While parenteral route is an efficient route for HCV transmission, recent emergence of sexually acquired HCV infections, particularly among HIV-positive MSM, has raised great concerns \[[@pone.0194149.ref009],[@pone.0194149.ref014]\]. Previous studies have suggested that HIV-positive individuals with higher CD4 counts experienced more sexually transmitted infections after they returned to a healthier status after initiation of combination antiretroviral therapy (cART). Improved survival and serosorting among the HIV-positive individuals has been proposed to be related to these outbreaks of sexually transmitted HCV infections among MSM \[[@pone.0194149.ref015],[@pone.0194149.ref016]\].

Few reports have investigated the changes of HCV seroprevalence among the HIV-positive individuals in the era of cART and harm reduction program for IDUs. In this multicenter study, we aimed to describe the seroepidemiology of HCV infection and to examine the evolution of HCV seroprevalence among HIV-positive Taiwanese in two study periods.

Materials and methods {#sec006}
=====================

Study setting and populations {#sec007}
-----------------------------

In Taiwan, the total number of HIV-positive patients reported to Taiwan Centers for Disease Control (CDC) was 34,479 as of 31 December 2016 since the first case of HIV infection diagnosed in 1984, with an estimated HIV prevalence of 126.4 per 100,000 populations. Before 2004, the majority of HIV infections occurred through sexual transmission, with MSM accounting for the largest proportion (48.2%), followed by heterosexuals (39.9%) \[[@pone.0194149.ref017]\]. However, an outbreak of HIV infection occurred among IDUs between 2003 and 2008; IDUs accounted for two-thirds of all cases of newly diagnosed HIV infection in 2005 and 2006. The outbreak of HIV infection was controlled with the rapid and sustained implementation of harm reduction program consisting of needle exchange and methadone maintenance programs in 2005 \[[@pone.0194149.ref018]\]. During the outbreak of HIV infection among IDUs, up to 96% of HIV-positive IDUs were co-infected with HCV \[[@pone.0194149.ref019]\]. Afterwards, sexual contact remained the leading mode of transmission for HIV infection, accounting for at least 89.9% of the reported cases of HIV infection in 2016 \[[@pone.0194149.ref017]\]. HIV care, including cART and monitoring of plasma HIV RNA load (PVL) and CD4 count, is provided free-of-charge at designated hospitals around Taiwan \[[@pone.0194149.ref020]\].

To understand the evolution of HCV seroprevalence among the HIV-positive individuals, two retrospective cohort studies were conducted at major designated hospitals in Taiwan. The methods and results of the first cohort that included 4,025 HIV-positive adults (aged ≥18 years) between 2004 and 2007 have been reported previously (2004--2007 cohort) \[[@pone.0194149.ref021]\]. The second cohort included the adults initiating cART between June 2012 and May 2016 (2012--2016 cohort). A similar case record form was used to collect their demographic and clinical characteristics including birth date, gender, route of HIV transmission, serological data of viral hepatitis and syphilis, CD4 lymphocyte count, and PVL at baseline and during follow-up. The study was approved by the Research Ethics Committee (National Taiwan University Hospital \[201003112R\] and Far Eastern Memorial Hospital \[105040-F\]), Medical Ethics and Institutional Review Board of Taoyuan General Hospital \[TYGH103011\], and Institutional Review Boards (Tri-Service General Hospital \[1-105-05-057\] National Taiwan University Hospital Hsin-Chu Branch \[105-017-F\], Taichung Veterans General Hospital \[CF16114B\], Chung Shan Medical University Hospital \[CS14034\], Changhua Christian Hospital \[160408\], Chia-Yi Christian Hospital \[105034\], National Cheng Kung University Hospital \[B-BR-105-038\], and Chi Mei Medical Center \[10505--002\]). The informed consent was waived.

Laboratory examinations {#sec008}
-----------------------

HIV infection was diagnosed by western blot test or detection of HIV viremia. Determinations of CD4 lymphocyte count and PVL, anti-HCV antibody, hepatitis B surface antigen (HBsAg) and anti-HBs antibody, anti-hepatitis A virus (HAV) antibody (HAV IgG), and the rapid plasma reagin (RPR) titer for syphilis were performed with the use of certified commercial kits at each participating hospital, and the results were collected locally and then pooled and analyzed.

Statistical analysis {#sec009}
--------------------

All statistical analyses were performed with the use of SPSS software version 21.0 (SPSS Inc., Chicago, IL, USA). Categorical variables, expressed as numbers and percentages, were compared using chi-squared test or Fisher's exact test. Continuous variables were expressed as means ± standard deviation (SDs) and were compared with Mann-Whitney U-test. A multiple logistic regression model was built to identify independent variables associated with anti-HCV seropositivity. All tests were two tailed and a *P* value of \<0.05 was considered significant.

Results {#sec010}
=======

In the 2004--2007 cohort, a total of 4,025 patients were included for analysis, with male predominance (n = 3,710, 92.2%) and a mean age of 38.6 years; among them, 1,478 (36.7%) patients acquired HIV through injecting drug use and 1,271 (31.6%) were MSM ([Table 1](#pone.0194149.t001){ref-type="table"}) \[[@pone.0194149.ref021]\]. In contrast, in the 2012--2016 cohort that included 3,856 HIV-positive patients, 625 (16.2%) were IDUs and 2,948 (76.5%) MSM ([Table 1](#pone.0194149.t001){ref-type="table"}). The mean CD4 lymphocyte count was 309.2 cells/μL (SD, 249 cells/μL) in the 2004--2007 cohort and 282 cells/μL (SD, 189 cells/μL) in the 2012--2016 cohort (*P*\<0.001). The late presenters, defined as CD4 ≤200 cells/μL at the first visit, composed of 37.0% and 34.1% of the patients in the 2004--2007 cohort and 2012--2016 cohort, respectively (*P* = 0.011). The mean PVL of the former cohort was significantly lower than that in the later cohort (4.41 vs 4.73 log~10~ copies/mL, *P*\<0.001).

10.1371/journal.pone.0194149.t001

###### Comparisons of demographic and clinical characteristics between the two cohorts.

![](pone.0194149.t001){#pone.0194149.t001g}

  Variables                                                 2004--2007 cohort        2012--2016 cohort        *P* value
  --------------------------------------------------------- ------------------------ ------------------------ -----------
  Male gender, n (%)                                        3,710 (92.0)             3,675 (95.3)             \<0.001
  Mean age (SD, range), years                               38.6 (11.1, 18--95)      33.1 (9.5, 18--84)       \<0.001
  Year of birth                                                                                               \<0.001
      before 1950                                           266 (6.6)                22 (0.6)                 
      1950--1959                                            449 (11.2)               102 (2.6)                
      1960--1969                                            1,178 (29.3)             387 (10)                 
      1970--1979                                            1,595 (39.6)             897 (23.3)               
      1980--1989                                            537 (13.3)               1,762 (45.7)             
      1990--2000                                            0                        686 (17.8)               
  Transmission risk group                                                                                     \<0.001
      Men who have sex with men                             1,271 (31.6)             2,948 (76.5)             
      Heterosexuals                                         582 (14.5)               236 (6.1)                
      Injecting drug users                                  1,478 (36.7)             625 (16.2)               
    Others/unknown                                          694 (17.2)               47 (1.2)                 
  Mean CD4 count (SD, range), cells/μL                      309.2 (249, 0--2,760)    282 (189, 0--2,217)      \<0.001
  Late presenter (CD4 ≤200 cells/μL), n/N\* (%)             1,269/3,432 (37.0)       1,278/3,749 (34.1)       0.011
  Mean plasma HIV RNA load (SD, range), log~10~ copies/mL   4.41 (1.03, 1.7--7.15)   4.73 (0.85, 1.3--7.55)   \<0.001
  HBsAg-positive, n/N (%)                                   618/3,805 (16.2)         412/3,776 (10.9)         \<0.001
  Anti-HCV-positive, n/N (%)                                1,288/2,974 (43.4)       707/3,793 (18.6)         \<0.001
  RPR titer ≥1:8, n/N (%)                                   255/1,636 (15.6)         400/2,407 (16.6)         0.382

Note: n/N: tests to be positive/tested number

Abbreviations: HBsAg, hepatitis B virus surface antigen; HCV, hepatitis C virus; RPR, rapid plasma reagin; SD: standard deviation

The prevalence of HBV/HIV and HCV/HIV co-infection in the 2004--2007 cohort was 16.2% and 43.4%, respectively, which was significantly higher than that in the 2012--2016 cohort (10.9% and 18.6%, respectively, *P*\<0.001). In the 2004--2007 and the 2012--2016 cohort, 15.6% and 16.6% of the patients tested had an RPR titer of 8 or greater, respectively (*P* = 0.382). The number of HIV-positive patients with dual infection with HBV and HCV was 246 out of 3008 patients assessed (8.2%) in the 2004--2007 cohort and 115 out of 3,759 patients (3.1%) in the 2012--2016 cohort (*P*\<0.001).

From 2004--2007 to 2012--2016, the overall HCV seroprevalence declined from 96.4% to 94.0% (*P* = 0.02) among IDUs and 5.9% to 3.5% (*P* = 0.002) among MSM; however, no significant change in HCV seroprevalence was observed among heterosexuals (9.4% vs. 10.9%, *P* = 0.59). The HCV seroprevalence in the two cohorts according to age-specific groups including \<20 years, 20--29, 30--39, 40--49, 50--59, and ≥60 years are shown in [Fig 1](#pone.0194149.g001){ref-type="fig"}. The HCV seroprevalence was significantly lower in the age groups between \<20 years to 30--39 years in the 2012--2016 cohort compared to that in the 2004--2007 cohort (*P*\<0.001), but was similar among those who were aged ≥40 years between the two cohorts and was higher in the age group of 50--59 years in the 2012--2016 cohort (*P*\<0.001), as shown in [Fig 1](#pone.0194149.g001){ref-type="fig"}. While the HCV seroprevalence among HIV-positive IDUs remained constantly high across all the age groups in the two cohorts, the overall HCV seroprevalence among MSM increased with age, from 3.3% in the patients aged 20--29 years to 13.9% in those aged ≥60 years in the 2004--2007 cohort, and from 2.8% in the patients aged 20--29 years to 13.8% in those aged 50--59 years in the 2012--2016 cohort ([Fig 1](#pone.0194149.g001){ref-type="fig"}). No significant difference was observed in HCV seroprevalence in each age group among MSM between these two cohorts. For the heterosexuals, the overall HCV seroprevalence according to age-specific groups, including 20--29, 30--39, 40--49, 50--59, and ≥60 years, was 15.6%, 8.3%, 8.4%, 7.2%, and 13.3%, respectively, for the 2004--2007 cohort; and the respective seroprevalence was 0%, 18.2%, 11.4%, 7.9%, and 15.0% for the 2012--2016 cohort.

![Seroprevalence of hepatitis C virus (HCV) infection among human immunodeficiency virus (HIV)-positive patients of different transmission routes and age groups in the 2004--2007 cohort and 2012--2016 cohort.\
IDUs: injecting drug users; MSM: men who have sex with men. \**P*\<0.001; ^\#^*P*\<0.05.](pone.0194149.g001){#pone.0194149.g001}

In the 2004--2007 cohort, the patients born between 1970 and 1979 had the highest HCV seroprevalence of 50.6%, while in the 2012--2016 cohort, the highest HCV seroprevalence (44.4%) occurred among the patients born between 1960 and 1969 ([Table 2](#pone.0194149.t002){ref-type="table"}). Among IDUs in the 2004--2007 cohort, the HCV seroprevalence was as high as 96.7% in the patients born between 1970 and 1979, while in the 2012--2016 cohort, the highest HCV seroprevalence (95.1%) was noted among patients born between 1950 and 1959. Among the HIV-positive MSM in the 2004--2007 cohort, the highest HCV seroprevalence was 14.3% in the patients born between 1950 and 1959 and the lowest seroprevalence was 1.4% in those born between 1980 and 1989; in the 2012--2016 cohort, the highest HCV seroprevalence was 14.3% in the patients born between 1950 and 1959, which decreased to 2.6% in those born between 1990 and 1999 ([Table 2](#pone.0194149.t002){ref-type="table"}).

10.1371/journal.pone.0194149.t002

###### HCV seroprevalence of HIV-positive patients of different transmission groups and birth years.

![](pone.0194149.t002){#pone.0194149.t002g}

  Year of birth   Patient number   All patients with available data   Injecting drug users   Men who have sex with men   Heterosexuals                                                   
  --------------- ---------------- ---------------------------------- ---------------------- --------------------------- ---------------- -------------- ---------------- -------------- -------------
  before 1950     288              32/194 (16.5)                      3/21 (14.3)            9/10 (90.0)                 1/2 (50.0)       5/43 (11.6)    0/8 (0)          13/97 (13.4)   2/10 (20.0)
  1950--1959      551              124/342 (36.3)                     44/101 (43.6)          84/87 (96.6)                39/41 (95.1)     14/98 (14.3)   4/28 (14.3)      10/104 (9.6)   1/28 (3.6)
  1960--1969      1,565            358/888 (40.3)                     167/376 (44.4)         301/313 (96.2)              150/161 (93.2)   16/316 (5.1)   10/159 (6.3)     11/158 (7.0)   6/50 (12.0)
  1970--1979      2,492            592/1,171 (50.6)                   317/880 (36.0)         500/517 (96.7)              286/301 (95.0)   23/420 (5.5)   22/523 (4.2)     7/86 (8.1)     9/49 (18.4)
  1980--1989      2,299            182/379 (48.0)                     157/1,737 (9.0)        159/165 (96.4)              100/107 (93.5)   2/140 (1.4)    49/1,545 (3.2)   3/23 (13.0)    7/70 (10.0)
  1990--2000      686              0                                  19/678 (18.6)          0                           577/614 (94.0)   0              17/2,907 (2.6)   0              0/23 (0)

n/N: tests to be positive/tested number

Two multivariate analyses to identify the factors associated with HCV seropositivity were conducted among the included patients ([Table 3](#pone.0194149.t003){ref-type="table"}); in model 1, only the patients acquiring HIV through sexual transmission were included, while in model 2, both patients acquiring HIV through sexual transmission and injecting drug use were included. The variables included in both analyses were age, gender, transmission route, baseline CD4 lymphocyte count, baseline PVL, HBsAg, and RPR ≥1:8. In model 1, 2,905 patients with all these variables available were included in the analysis. The adjusted odds ratio (aOR) was 1.03 for per 1-year increase (95% confidence interval \[CI\] 1.02--1.05). Compared with heterosexuals, the aOR for HCV seropositivity among MSM was 0.47 (95% CI, 0.31--0.72). Among those with RPR test results, the aOR for HCV seropositivity among the patients with an RPR titer ≥1:8 was 1.58 (95% CI, 1.03--2.43). In model 2, 3,289 patients were included for analysis. The aOR for per 1-year increase was similar to that of model 1. Compared with heterosexuals, the aOR for HCV seropositivity among MSM was 0.43 (95% CI, 0.28--0.66). Among those with RPR test results, the aOR for HCV seropositivity among the patients with an RPR titer ≥1:8 was 1.49 (95% CI, 0.99--2.26).

10.1371/journal.pone.0194149.t003

###### Multivariate analyses[\*](#t003fn001){ref-type="table-fn"} of associated factors with seropositivity of hepatitis C virus among patients who acquired HIV through sexual transmission and injecting drug use.
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  Variables                        HCV seropositivity                                                           
  -------------------------------- -------------------- -------------- --------------- --------- -------------- ---------
  Age, per 1-year increase         1.03                 1.02--1.05     \<0.001         1.03      1.02--1.05     \<0.001
  Transmission route                                                                                            
      Heterosexual contact         Reference            Reference                                               
      Male-to-male contact         0.47                 0.31--0.73     0.001           0.43      0.28--0.66     \<0.001
      Injecting drug use           Not applicable       84.13          50.94--138.96   \<0.001                  
  Baseline CD4 count               1.001                1.000--1.001   0.168           1.001     1.000--1.002   0.003
  Rapid plasma reagin titer ≥1:8   1.58                 1.03--2.43     0.038           1.49      0.99--2.26     0.059

\*Variables included were age, gender, transmission route, baseline CD4 number and plasma HIV RNA load, positive hepatitis B surface antigen, and a rapid plasma reagin titer ≥1:8.

^a^ Model 1 only included patients acquiring HIV through sexual transmission for analysis.

^b^ Model 2 included patients acquiring HIV through sexual transmission and injecting drug use for analysis.

When the multivariate analyses were repeated separately in each cohort ([S1 Table](#pone.0194149.s001){ref-type="supplementary-material"}), we found that the associations between age and transmission route with HCV seropositivity remained similar, but, while CD4 count was significantly associated with HCV seropositivity in the two cohorts, the statistically significant association between an RPR titer≥1:8 and HCV seropositivity was only observed in the 2012--2016 cohort.

Discussion {#sec011}
==========

The present study demonstrates that the overall HCV seroprevalence has declined among the HIV-positive patients in Taiwan in the post-cART era, though HIV-positive IDUs consistently had the highest HCV seroprevalence across all age groups. On the other hand, the finding of a lower HCV seroprevalence that increased with age among HIV-positive MSM of the later birth cohort were quite similar to that observed in the general population in Taiwan \[[@pone.0194149.ref022]\]. Traditional factors such as use of contaminated blood products or unsterile equipment or devices in the medical facilities that used to contribute to the previous hyperendemicity of HCV infection among the general population in Taiwan in earlier years were less likely to present for the younger population \[[@pone.0194149.ref005],[@pone.0194149.ref022]--[@pone.0194149.ref024]\]. However, sharing needles and diluents continue to be the major risky behavior related to transmission of both HIV and HCV among HIV-positive IDUs \[[@pone.0194149.ref025]\].

Previous studies have found that the HCV seroprevalence increased along with time despite the cohort effects \[[@pone.0194149.ref005],[@pone.0194149.ref007]\]. In the Italian Health Longitudinal Patient Database, HCV seroprevalence increased from 0.24% in 2002 to 0.5% in 2012 \[[@pone.0194149.ref010]\]. With an 8-fold increase over time, HCV seroprevalence in Czech Republic increased from 0.2% in 2001 to 1.67% in 2015 \[[@pone.0194149.ref026]\]. However, our study found a decline in the HCV seroprevalence among the HIV-positive patients in the two study cohorts, though the incidence of recent HCV infection from sexually transmitted routes was increasing in recent reports \[[@pone.0194149.ref009],[@pone.0194149.ref015],[@pone.0194149.ref027]\]. The significant decline of HCV seroprevalence in our study is likely attributed to the changing composition of risk groups for HIV transmission between the two cohorts. IDUs had the highest HCV seroprevalence among the HIV-positive patients. In the 2004--2007 cohort, IDUs accounted for 36.7% of the patients included, which decreased to 16.2% in the 2012--2016 cohort; moreover, the patients in the 2012--2016 cohort were significantly younger that those in the 2004--2007 cohort (33.1 *vs*. 38.6 years, *P*\<0.001).

Despite of the overall decline of HCV seroprevalence, different patterns of changes of HCV seroprevalence were observed among different risk groups. Compared with IDUs, HCV seroprevalence was much lower among HIV-positive MSM and heterosexuals. With the implementation of harm reduction program to effectively control the HIV outbreak among IDUs between 2003 and 2008, the number of new HIV infections through injecting drug use has decreased dramatically, which only constituted 3.5% of new HIV infections in 2016 \[[@pone.0194149.ref017],[@pone.0194149.ref028],[@pone.0194149.ref029]\]. However, the HCV seroprevalence remains high among the IDUs, with only 2.4% decrease from 96.4% in the 2004--2007 cohort to 94.0% in the 2012--2016 cohort. The findings suggest that sustained harm reduction program is needed to achieve the great impact on reduction of HCV transmission among IDUs in the long-term.

In this study, we found that younger HIV-positive MSM had a lower HCV seroprevalence in our two cohorts, consistent with the trends among the general population \[[@pone.0194149.ref022],[@pone.0194149.ref023]\]. Among these sexually transmitted HIV-positive patients, the correlation between syphilis and HCV seropositivity in multivariate analysis suggests that some of the patients in our cohort might acquire HCV infection through sexual transmission \[[@pone.0194149.ref015],[@pone.0194149.ref016]\]. Recent studies have shown significantly higher risks of HCV seroconversion among MSM compared to heterosexuals and the association with sexually transmitted infections, traumatic sex, and use of recreational drugs among MSM \[[@pone.0194149.ref030],[@pone.0194149.ref031]\]. However, our cross-sectional study shows that HIV-positive MSM had a lower HCV seroprevalence than HIV-positive heterosexuals in our multivariable analysis. The reason for this finding is not clear. However, the misclassification of transmission routes might occur. Some IDUs with HCV infection would report themselves as heterosexuals because of concerns of legal liability. In addition, the finding that HCV seroprevalence increased with age was only noted in MSM, but not heterosexuals, as shown in [Fig 1](#pone.0194149.g001){ref-type="fig"}. This phenomenon also suggests a mixture of sexual and IDU transmission in our heterosexual population. Annual follow-up of incident HCV infection is warranted among the at-risk populations because, similar to what has been reported in the developed countries, recent studies have shown that increasing HCV seroconversion among MSM \[[@pone.0194149.ref015],[@pone.0194149.ref032]\].

There are several limitations in our study. First, while this was a multicenter study with the patients from several designed hospitals for HIV care around Taiwan in these two cohorts, the participating hospitals were not completely identical in these two cohorts. However, free-of-charge HIV care is provided according to the updated national treatment guidelines and the differences in terms of HCV testing rates between two cohorts would be limited. Second, In the 2004--2007 cohort, any patient who sought HIV care at the participating hospitals was included regardless of antiretroviral treatment experience. The later cohort, instead, only included those HIV-positive patients who were antiretroviral-naïve. Since all of the data from the included patients from different hospitals did not contain personal identifiers, we were not able to exclude the possibility that some of the patients might be included in both cohorts. However, by compared birth date, gender, and transmission route between the two cohorts, we found that less than 10% of patients in both cohorts shared the identical clinical characteristics. Third, the misclassification of risk groups of HIV transmission might confound the findings of HCV seroprevalence among different groups in that heterosexuals or MSM who were IDUs might not identify themselves as IDUs because of concerns about legal liability. Fourth, we used an RPR titer ≥1:8 as a cut-off value for presumed syphilitic infection in the analysis; however, RPR titers might be falsely positive, especially among the IDUs with HCV infection. Therefore, in our multivariate analysis that included only sexually transmitted HIV-positive patients, the results were similar. In the meanwhile, using RPR ≥1:16 and RPR ≥1:32 as cut-off values also yielded the independent association with HCV seropositivity (aOR, 1.83 \[95% CI, 1.17--2.85\] for RPR ≥1:16 and aOR, 2.20 \[95% CI, 1.40--3.47\] for RPR ≥1:32) (data not shown).

In conclusion, we found that, in these two cross-sectional studies conducted approximately 10-year apart, HCV seroprevalence among HIV-infected patients decreased with time. HCV infection remained highly prevalent among IDUs among all age groups, but HCV seroprevalence among HIV-infected MSM has declined in the later cohort with an increased number of patients in the young age groups. Co-infection with syphilis was an independent associated factor with HCV seropositivity among sexually transmitted HIV-positive patients.
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